AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$KMTS

Ford Alfred J Jr sold $151K of KMTS

Ford Alfred J Jr (Chief Commercial Officer) sold 6,275 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $24.09 ($0.15M total) on 2026-08-04.

Original reporting
SEC EDGAR · Ford Alfred J Jr
Published Aug 6, 2026, 11:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the CCO: 6,275 shares at $24.0862 on 2026-08-04, totaling $151,140.90, with post-sale holdings of 99,564 shares and no disclosed pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone is unlikely to change valuation without corroborating company news.

03

What to watch

The filing does not state motivations, remaining option/RSU activity, or whether other insiders are buying/selling around the same period.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06 after-hours; sale dated 2026-08-04

Background

The article is a primary-source SEC Form 4 insider transaction for Keystra Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Insider Form 4 shows CCO Alfred J. Ford Jr sold 6,275 shares of KMTS for about $151.1K on 2026-08-04.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional fundamental signal from the filing alone.

Evidence & confidence

The disclosure is a Form 4 insider transaction, not earnings, guidance, or a corporate event. The article provides sale size and price but no accompanying company-specific news.

Market effects

Sector

Minimal. Insider sales in a single small-cap medical technology name typically do not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification, taxes, or planned liquidity needs; without a 10b5-1 plan, it still does not imply negative company fundamentals.

Key entities

  • issuer
    KMTS

    Keystra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Ford Alfred J Jr

    Chief Commercial Officer who sold shares via an open-market sale.

Read at source← All news

Related articles

JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min
JUL 15
$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

yahoo.com7 min
JUL 14
$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.

manilatimes.net4 min